Video

Kay Verble Discusses a Study to Characterize Long-Term Survivors of GBM

Author(s):

Kay Verble

Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Kay Verble, from the Sontag Foundation and Brain Tumor Network, discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Rick Sontag, one of our 2015 GBM Heroes, is an entrepreneur who has worked to improve the lives of patients with GBM and other brain tumors through a multifaceted approach to engaging and supporting the brightest scientific minds in brain cancer research.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content
Image of brain.
July 17th 2025

FDA Grants Orphan Status to Liquid Glioma Treatment SH-110

Spencer Feldman
SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to swallow pills access therapy.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
Image of brain tumor.
July 7th 2025

FDA Grants Orphan Drug Status to MB-101 for Glioblastoma, Astrocytomas

Spencer Feldman
The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
Image of women with blonde hair.
June 23rd 2025

Living My Best Life: A Family Beach Vacation After a Brain Tumor

Julie S. Brokaw
After a brain tumor diagnosis and infection, I celebrate recovery with family at the beach, embracing life’s precious moments together.
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.